Interleukin-17 (IL-17) Inhibitors in the Treatment of Plaque Psoriasis: A Review.

Interleukin-17 (IL-17) Inhibitors in the Treatment of Plaque Psoriasis: A Review.
Skin Therapy Lett. 2015 Feb;20(1):1-5
Authors: Gooderham M, Posso-De Los Rios CJ, Rubio-Gomez GA, Papp K
Abstract
Acting on keratinocytes to produce antimicrobial peptides and chemokines, which in turn attract neutrophils and other inflammatory cells, interleukin-17 (IL-17) is believed to be a potent driver of plaque psoriasis. Its proinflammatory characteristics make IL-17 an attractive therapeutic target for addressing immune dysregulation. This review examines the role of IL-17 in the pathogenesis of plaque psoriasis and the potential implications of its inhibition. The efficacy and safety results from Phase 2 and 3 trials with monoclonal antibodies targeting IL-17RA (brodalumab), and IL-17A (ixekizumab and secukinumab) validate IL-17 as an effective therapeutic target for the treatment of plaque psoriasis.
PMID: 25807214 [PubMed - in process]

Source: Skin Therapy Letter - February 1, 2015 Category: Dermatology Authors: Gooderham M, Posso-De Los Rios CJ, Rubio-Gomez GA, Papp K Tags: Skin Therapy Lett Source Type: research